North America Real World Evidence Solutions Market Size, Share & Trends Analysis Report By Component, By Application, By End Use, By Therapeutic Area, By Country, And Segment Forecasts, 2026 - 2033

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Component
  • 1.2.2. Application
  • 1.2.3. End Use
  • 1.2.4. Therapeutic Area
• 1.3. Estimates and Forecast Timeline
• 1.4. Research Methodology
• 1.5. Information Procurement
  • 1.5.1. Purchased Database
  • 1.5.2. GVR's Internal Database
  • 1.5.3. Secondary Sources
  • 1.5.4. Primary Research
• 1.6. Information Analysis
  • 1.6.1. Data Analysis Models
• 1.7. Market Formulation & Data Visualization
• 1.8. Model Details
  • 1.8.1. Commodity Flow Analysis
• 1.9. List of Secondary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. High adoption of electronic health records (EHRs) and digital health technologies
    • 3.2.1.2. Advancements in big data analytics, artificial intelligence, and cloud-based healthcare platforms
    • 3.2.1.3. Increasing demand for real-world data to support drug development and clinical research
    • 3.2.1.4. Expansion of healthcare databases, patient registries, and claims data sources
    • 3.2.1.5. Growing need for cost-effective healthcare and value-based care models
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. Data privacy and security concern
    • 3.2.2.2. High cost of implementing advanced analytics and data integration platforms.
    • 3.2.2.3. Data quality and interoperability challenges
  • 3.2.3. Industry Opportunity Analysis
  • 3.2.4. Industry Challenge Analysis
  • 3.2.5. Pricing Analysis
  • 3.2.6. Emerging Trends
• 3.3. Business Environment Analysis
  • 3.3.1. Porter's Five Forces Analysis
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTLE Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Economic and Social landscape
    • 3.3.2.3. Technological landscape
    • 3.3.2.4. Environmental landscape
    • 3.3.2.5. Legal Landscape
  • 3.3.3. Market Opportunity analysis
  • 3.3.4. Market Challenges analysis

Chapter 4. North America Real World Evidence Solutions Market: Component Estimates & Trend Analysis

• 4.1. Component Segment Dashboard
• 4.2. Component Market Share Movement Analysis, 2025 & 2033
• 4.3. Market Size & Forecasts and Trend Analysis, by Component, 2021 to 2033 (USD Million)
• 4.4. Services
  • 4.4.1. Services market estimates and forecasts 2021 to 2033 (USD Million)
• 4.5. Data Sets
  • 4.5.1. Data sets market estimates and forecasts 2021 to 2033 (USD Million)
  • 4.5.2. Clinical Settings Data
    • 4.5.2.1. Clinical Settings Data market estimates and forecasts 2021 to 2033 (USD Million)
  • 4.5.3. Claims Data
    • 4.5.3.1. Claims Data market estimates and forecasts 2021 to 2033 (USD Million)
  • 4.5.4. Pharmacy Data
    • 4.5.4.1. Pharmacy Data market estimates and forecasts 2021 to 2033 (USD Million)
  • 4.5.5. Patient-Powered Data
    • 4.5.5.1. Patient Powered Data market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 5. North America Real World Evidence Solutions Market: Application Estimates & Trend Analysis

• 5.1. Application Segment Dashboard
• 5.2. Application Market Share Movement Analysis, 2025 & 2033
• 5.3. Market Size & Forecasts and Trend Analysis, by Application, 2021 to 2033 (USD Million)
• 5.4. Drug Development & Approvals
  • 5.4.1. Drug development & approval market estimates and forecasts 2021 to 2033 (USD Million)
• 5.5. Medical Device Development & Approvals
  • 5.5.1. Medical device development & approvals market estimates and forecasts 2021 to 2033 (USD Million)
• 5.6. Reimbursement/Coverage and Regulatory Decision Making
  • 5.6.1. Reimbursement/Coverage and Regulatory Decision Making market estimates and forecasts 2021 to 2033 (USD Million)
• 5.7. Post Market Safety & Adverse Events Monitoring
  • 5.7.1. Post Market Safety & Adverse Events Monitoring market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 6. North America Real World Evidence Solutions Market: End Use Estimates & Trend Analysis -

• 6.1. End Use Dashboard
• 6.2. End Use Market Share Movement Analysis, 2025& 2033
• 6.3. Market Size & Forecasts and Trend Analysis, by End Use, 2021 to 2033 (USD Million)
• 6.4. Healthcare Companies (Pharmaceutical, Biopharmaceutical, Medical Device)
  • 6.4.1. Healthcare Companies (Pharmaceutical, Biopharmaceutical, Medical Device) market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.4.2. Clinical research
    • 6.4.2.1. Clinical research market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.4.3. Commercial (inclusive of marketing, etc.)
    • 6.4.3.1. Commercial (inclusive of marketing, etc.) market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.4.4. HEOR
    • 6.4.4.1. HEOR market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.4.5. Others (market access, etc.)
    • 6.4.5.1. Others (market access, etc.) market estimates and forecasts 2021 to 2033 (USD Million)
• 6.5. Healthcare Payers
  • 6.5.1. Healthcare Payers market estimates and forecasts 2021 to 2033 (USD Million)
• 6.6. Healthcare Providers
  • 6.6.1. Healthcare Providers market estimates and forecasts 2021 to 2033 (USD Million)
• 6.7. Others
  • 6.7.1. Others market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 7. North America Real World Evidence Solutions Market: Therapeutic Area Estimates & Trend Analysis

• 7.1. Therapeutic Area Segment Dashboard
• 7.2. Therapeutic Area Market Share Movement Analysis, 2025 & 2033
• 7.3. Market Size & Forecasts and Trend Analysis, by Therapeutic Area, 2021 to 2033 (USD Million)
• 7.4. Oncology
  • 7.4.1. Oncology market estimates and forecasts 2021 to 2033 (USD Million)
• 7.5. Cardiology
  • 7.5.1. Cardiology market estimates and forecasts 2021 to 2033 (USD Million)
• 7.6. Diabetes
  • 7.6.1. Diabetes market estimates and forecasts 2021 to 2033 (USD Million)
• 7.7. Neurology
  • 7.7.1. Neurology market estimates and forecasts 2021 to 2033 (USD Million)
• 7.8. Psychiatry
  • 7.8.1. Psychiatry market estimates and forecasts 2021 to 2033 (USD Million)
• 7.9. Respiratory
  • 7.9.1. Respiratory market estimates and forecasts 2021 to 2033 (USD Million)
• 7.10. Other Therapeutic Areas (Immunology, Gastroenterology, etc.)
• 7.11. Other Therapeutic Areas (Immunology, Gastroenterology, etc.) market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 8. North America Real World Evidence Solutions Market: Country Estimates & Trend Analysis

• 8.1. Country Market Dashboard
• 8.2. Country Market: Key Takeaways
• 8.3. U.S.
  • 8.3.1. Key country dynamic
  • 8.3.2. Regulatory framework
  • 8.3.3. Competitive insights
  • 8.3.4. U.S. Real World Evidence Solutions market estimates and forecasts, 2021-2033 (USD Million)
• 8.4. Canada
  • 8.4.1. Key country dynamic
  • 8.4.2. Regulatory framework
  • 8.4.3. Competitive insights
  • 8.4.4. Canada Real World Evidence Solutions market estimates and forecasts, 2021-2033 (USD Million)
• 8.5. Mexico
  • 8.5.1. Key country dynamic
  • 8.5.2. Regulatory framework
  • 8.5.3. Competitive insights
  • 8.5.4. Mexico Real World Evidence Solutions market estimates and forecasts, 2021-2033 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Company Market Position Analysis, 2025
• 9.2. Company Categorization
• 9.3. Company Profiles/Listing
  • 9.3.1. IQVIA
    • 9.3.1.1. Overview
    • 9.3.1.2. Financial performance
    • 9.3.1.3. Product benchmarking
    • 9.3.1.4. Strategic initiatives
  • 9.3.2. Merative
    • 9.3.2.1. Overview
    • 9.3.2.2. Financial performance
    • 9.3.2.3. Product benchmarking
    • 9.3.2.4. Strategic initiatives
  • 9.3.3. PPD Inc. (now part of Thermo Fisher)
    • 9.3.3.1. Overview
    • 9.3.3.2. Financial performance
    • 9.3.3.3. Product benchmarking
    • 9.3.3.4. Strategic initiatives
  • 9.3.4. Parexel International Corporation
    • 9.3.4.1. Overview
    • 9.3.4.2. Financial performance
    • 9.3.4.3. Product benchmarking
    • 9.3.4.4. Strategic initiatives
  • 9.3.5. Icon Plc
    • 9.3.5.1. Overview
    • 9.3.5.2. Financial performance
    • 9.3.5.3. Product benchmarking
    • 9.3.5.4. Strategic initiatives
  • 9.3.6. Oracle
    • 9.3.6.1. Overview
    • 9.3.6.2. Financial performance
    • 9.3.6.3. Product benchmarking
    • 9.3.6.4. Strategic initiatives
  • 9.3.7. Syneos Health
    • 9.3.7.1. Overview
    • 9.3.7.2. Financial performance
    • 9.3.7.3. Product benchmarking
    • 9.3.7.4. Strategic initiatives
  • 9.3.8. Cegedim Health Data
    • 9.3.8.1. Overview
    • 9.3.8.2. Financial performance
    • 9.3.8.3. Product benchmarking
    • 9.3.8.4. Strategic initiatives
  • 9.3.9. Medpace
    • 9.3.9.1. Overview
    • 9.3.9.2. Financial performance
    • 9.3.9.3. Product benchmarking
    • 9.3.9.4. Strategic initiatives
  • 9.3.10. Optum Inc. (UnitedHealth Group)
    • 9.3.10.1. Overview
    • 9.3.10.2. Financial performance
    • 9.3.10.3. Product benchmarking
    • 9.3.10.4. Strategic initiatives
  • 9.3.11. SAS Institute Inc.
    • 9.3.11.1. Overview
    • 9.3.11.2. Financial performance
    • 9.3.11.3. Product benchmarking
    • 9.3.11.4. Strategic initiatives
  • 9.3.12. Cognizant
    • 9.3.12.1. Overview
    • 9.3.12.2. Financial performance
    • 9.3.12.3. Product benchmarking
    • 9.3.12.4. Strategic initiatives
  • 9.3.13. Aetion, Inc. (acquired by Datavant in May 2025)
    • 9.3.13.1. Overview
    • 9.3.13.2. Financial performance
    • 9.3.13.3. Product benchmarking
    • 9.3.13.4. Strategic initiatives
  • 9.3.14. Flatiron Health
    • 9.3.14.1. Overview
    • 9.3.14.2. Financial performance
    • 9.3.14.3. Product benchmarking
    • 9.3.14.4. Strategic initiatives
  • 9.3.15. Cytel Inc.
    • 9.3.15.1. Overview
    • 9.3.15.2. Financial performance
    • 9.3.15.3. Product benchmarking
    • 9.3.15.4. Strategic initiatives
  • 9.3.16. Trinity
    • 9.3.16.1. Overview
    • 9.3.16.2. Financial performance
    • 9.3.16.3. Product benchmarking
    • 9.3.16.4. Strategic initiatives
  • 9.3.17. NTT Data Inc.
    • 9.3.17.1. Overview
    • 9.3.17.2. Financial performance
    • 9.3.17.3. Product benchmarking
    • 9.3.17.4. Strategic initiatives

List of Table

• Table 1 List of abbreviations
• Table 2 List of secondary data sources
• Table 3 North America Real World Evidence Solutions market, by country, 2021 - 2033 (USD Million)
• Table 4 North America Real World Evidence Solutions market, by component, 2021 - 2033 (USD Million)
• Table 5 North America Real World Evidence Solutions market, by application, 2021 - 2033 (USD Million)
• Table 6 North America Real World Evidence Solutions market, by end use, 2021 - 2033 (USD Million)
• Table 7 North America Real World Evidence Solutions market, by therapeutic area, 2021 - 2033 (USD Million)
• Table 8 U.S Real World Evidence Solutions market, by component, 2021 - 2033 (USD Million)
• Table 9 U.S Real World Evidence Solutions market, by application, 2021 - 2033 (USD Million)
• Table 10 U.S Real World Evidence Solutions market, by end use, 2021 - 2033 (USD Million)
• Table 11 U.S Real World Evidence Solutions market, by therapeutic area, 2021 - 2033 (USD Million)
• Table 12 Canada Real World Evidence Solutions market, by component, 2021 - 2033 (USD Million)
• Table 13 Canada Real World Evidence Solutions market, by application, 2021 - 2033 (USD Million)
• Table 14 Canada Real World Evidence Solutions market, by end use, 2021 - 2033 (USD Million)
• Table 15 Canada Real World Evidence Solutions market, by therapeutic area, 2021 - 2033 (USD Million)
• Table 16 Mexico Real World Evidence Solutions market, by component, 2021 - 2033 (USD Million)
• Table 17 Mexico Real World Evidence Solutions market, by application, 2021 - 2033 (USD Million)
• Table 18 Mexico Real World Evidence Solutions market, by end use, 2021 - 2033 (USD Million)
• Table 19 Mexico Real World Evidence Solutions market, by therapeutic area, 2021 - 2033 (USD Million)

List of Figures

• Fig. 1 Market research process
• Fig. 2 Data triangulation techniques
• Fig. 3 Market formulation & validation
• Fig. 4 North America Real World Evidence Solutions market: Market outlook
• Fig. 5 North America Real World Evidence Solutions market: Segment outlook
• Fig. 6 North America Real World Evidence Solutions market: Competitive landscape outlook
• Fig. 7 Parent market outlook
• Fig. 8 North America Real World Evidence Solutions Market Driver Impact
• Fig. 9 North America Real World Evidence Solutions Market Restraint Impact
• Fig. 10 North America Real World Evidence Solutions market, Component outlook key takeaways (USD Million)
• Fig. 11 North America Real World Evidence Solutions market: Component movement analysis (USD Million)
• Fig. 12 Services market, 2021 - 2033 (USD Million)
• Fig. 13 Data sets market, 2021 - 2033 (USD Million)
• Fig. 14 Clinical settings data market, 2021 - 2033 (USD Million)
• Fig. 15 Claim data market, 2021 - 2033 (USD Million)
• Fig. 16 Pharmacy market, 2021 - 2033 (USD Million
• Fig. 17 Patient-powered data market, 2021 - 2033 (USD Million)
• Fig. 18 North America Real World Evidence Solutions market, Application outlook: Key takeaways, (USD Million)
• Fig. 19 North America Real World Evidence Solutions market: Application movement analysis (USD Million)
• Fig. 20 Drug development & approvals market, 2021 - 2033 (USD Million)
• Fig. 21 Medical device development & approvals market, 2021 - 2033 (USD Million)
• Fig. 22 Reimbursement/coverage & regulatory decision-making market, 2021 - 2033 (USD Million)
• Fig. 23 Post market safety & adverse events monitoring market, 2021 - 2033 (USD Million)
• Fig. 24 North America Real World Evidence Solutions market, End use outlook key takeaways (USD Million)
• Fig. 25 North America Real World Evidence Solutions market: End use movement analysis (USD Million)
• Fig. 26 Healthcare companies' market, 2021 - 2033 (USD Million)
• Fig. 27 Clinical research market, 2021 - 2033 (USD Million)
• Fig. 28 Commercial research market, 2021 - 2033 (USD Million)
• Fig. 29 HEOR market, 2021 - 2033 (USD Million)
• Fig. 30 Others market, 2021 - 2033 (USD Million)
• Fig. 31 Healthcare payers' market, 2021 - 2033 (USD Million)
• Fig. 32 Healthcare providers market, 2021 - 2033 (USD Million)
• Fig. 33 Others market, 2021 - 2033 (USD Million)
• Fig. 34 North America Real World Evidence Solutions market, Therapeutic area outlook key takeaways (USD Million)
• Fig. 35 North America Real World Evidence Solutions market: Therapeutic area movement analysis, (USD Million)
• Fig. 36 Oncology market, 2021 - 2033 (USD Million)
• Fig. 37 Cardiology market, 2021 - 2033 (USD Million)
• Fig. 38 Neurology market, 2021 - 2033 (USD Million)
• Fig. 39 Diabetes market, 2021 - 2033 (USD Million)
• Fig. 40 Psychiatry market, 2021 - 2033 (USD Million)
• Fig. 41 Respiratory market, 2021 - 2033 (USD Million)
• Fig. 42 Other therapeutic areas market, 2021 - 2033 (USD Million)
• Fig. 43 Country marketplace: Key takeaways
• Fig. 44 North America Real World Evidence Solutions market: Country outlook, 2025 & 2033
• Fig. 45 U S Real World Evidence Solutions market estimates and forecasts, 2021 - 2033 (USD Million)
• Fig. 46 Canada Real World Evidence Solutions market estimates and forecasts, 2021 - 2033 (USD Million)
• Fig. 47 Mexico Real World Evidence Solutions market estimates and forecasts, 2021 - 2033 (USD Million)